Paige Mahaney - C4 Therapeutics Chief Officer
| CCCC Stock | USD 4.55 0.36 8.59% |
Executive
Paige Mahaney is Chief Officer of C4 Therapeutics
| Address | 490 Arsenal Way, Watertown, MA, United States, 02472 |
| Phone | 617 231 0700 |
| Web | https://www.c4therapeutics.com |
C4 Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2061) % which means that it has lost $0.2061 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.46) %, meaning that it created substantial loss on money invested by shareholders. C4 Therapeutics' management efficiency ratios could be used to measure how well C4 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.37. In addition to that, Return On Capital Employed is expected to decline to -0.44. At present, C4 Therapeutics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.20, whereas Total Assets are forecasted to decline to about 362.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Michael Naso | Century Therapeutics | N/A | |
| Ronald MD | Arvinas | 58 | |
| Lisa Sinclair | Arvinas | N/A | |
| Angela Cacace | Arvinas | 56 | |
| Madhu Pudipeddi | Prelude Therapeutics | N/A | |
| Saurabh Sewak | Foghorn Therapeutics | N/A | |
| John Grosso | Arvinas | 67 | |
| Danielle Bradbury | Mineralys Therapeutics, Common | N/A | |
| Bryant JD | Prelude Therapeutics | 53 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| Anna Rivkin | Foghorn Therapeutics | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Suresh Silva | Shattuck Labs | N/A | |
| Kelli MS | Shattuck Labs | N/A | |
| Jeremy Chadwick | Kymera Therapeutics | 61 | |
| Michael Covarrubias | Rezolute | N/A | |
| John Moore | Edgewise Therapeutics | 60 | |
| John JD | Edgewise Therapeutics | 60 | |
| Michael MD | Century Therapeutics | 53 | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 |
C4 Therapeutics Leadership Team
Elected by the shareholders, the C4 Therapeutics' board of directors comprises two types of representatives: C4 Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CCCC. The board's role is to monitor C4 Therapeutics' management team and ensure that shareholders' interests are well served. C4 Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, C4 Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paige Mahaney, Chief Officer | ||
| Kelly Schick, Chief Officer | ||
| Andrew MBA, President CEO | ||
| Isabel Chiu, Senior Development | ||
| Mr MBA, Chief Officer | ||
| Andrew Hirsch, Pres CEO | ||
| Leonard MD, Chief Officer | ||
| Roy Pollock, Senior Sciences | ||
| Lauren White, Chief Officer | ||
| Christopher Nasveschuk, Senior Chemistry | ||
| Stewart Fisher, Chief Officer | ||
| Courtney Solberg, Senior Relations | ||
| Kendra Adams, Chief Officer | ||
| Mayra ReyesArmour, Quality Operations | ||
| Jolie JD, Chief Secretary | ||
| Mark Mossler, Chief Officer | ||
| Nathanael Gray, CoFounder Board | ||
| Kristina Zambouras, Director HR |
CCCC Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is C4 Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (1.84) % | ||||
| Current Valuation | 132.63 M | ||||
| Shares Outstanding | 70.59 M | ||||
| Shares Owned By Insiders | 11.43 % | ||||
| Shares Owned By Institutions | 91.64 % | ||||
| Number Of Shares Shorted | 7.4 M | ||||
| Price To Book | 1.32 X | ||||
| Price To Sales | 9.54 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.522 | Quarterly Revenue Growth 0.387 | Return On Assets (0.21) | Return On Equity (0.46) |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.